Blog
    Peptide SpotlightFor PatientsApril 21, 2026

    What is Semax and how does this brain peptide work?

    Learn about Semax, a peptide fragment of the ACTH hormone used in Russia for stroke and brain health, and why it is not currently FDA-approved in the U.S.

    What is this stuff, exactly?

    Semax is a lab-made version of a small piece of a hormone called ACTH. Specifically, it is based on the ACTH(4-10) fragment.

    While that sounds like a line from a sci-fi movie, its main job is to boost something called BDNF (brain-derived neurotrophic factor). Think of BDNF as a protein that helps support and protect your brain cells.

    How does it work without making me jittery?

    Usually, hormones like ACTH affect your adrenal glands—the little hats on your kidneys that manage stress.

    Semax is clever because it provides neuroprotection (guarding your brain cells) without those hormonal side effects. It works by adjusting your dopamine and serotonin systems, which are the chemical messengers in your brain that handle things like mood and focus.

    Is it actually a new discovery?

    If you live in the United States, it feels brand new. However, doctors in Russia have been using it as a standard treatment for ischemic stroke (a stroke caused by a blocked blood vessel) since the 1990s.

    It has over 25 years of history in Russian clinics. They have even used a special type of brain scan called an fMRI to confirm that it actually does something to brain activity.

    Why haven't I heard of it from my local pharmacy?

    Here is where the "it's complicated" relationship status comes in. While Russia has approved it for over two decades, it is not FDA-approved in the United States.

    Scientists call this a "Western validation" gap. We have a lot of data from Russia, but we do not have large Western RCTs (Randomized Controlled Trials), which are the gold-standard tests used by U.S. regulators.

    What should you watch out for?

    Because the rules are different depending on where you live, the regulatory landscape is a bit messy.

    • The FDA listed it under Category 2 in September 2023, which means they have concerns about it being used in certain pharmacy settings.
    • A warning letter was also issued back in 2020 regarding its sale.
    • Currently, it is not listed as being in a shortage, mostly because it is not a standard U.S. medicine.

    This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    selankcerebrolysin

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.